L870-0113 Screening compound: methyl 2-[(3-{[1-(4-fluorophenyl)-N-phenylformamido]methyl}-1-methyl-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-5-carbonyl)amino]propanoate

L870-0113 Screening compound: methyl 2-[(3-{[1-(4-fluorophenyl)-N-phenylformamido]methyl}-1-methyl-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-5-carbonyl)amino]propanoate
L870-0113 Screening compound: methyl 2-[(3-{[1-(4-fluorophenyl)-N-phenylformamido]methyl}-1-methyl-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-5-carbonyl)amino]propanoate alternative view

Chemical Structure Depiction of ChemDiv screening compound L870-0113
methyl 2-[(3-{[1-(4-fluorophenyl)-N-phenylformamido]methyl}-1-methyl-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-5-carbonyl)amino]propanoate

Available from 1 mg

Formats:

  • Glass Vials (4ml Glass Vials VWR #97047-678)
  • 96-tube racks (Matrix #4247 96-well 1.4ml sealed with capmats, empty cols 1 & 12, 100uL of 10mM)

Shiptime: 1 week worldwide delivery in most cases

Compound Identifiers

ChemDiv Compound ID

L870-0113

Molecular Formula

C26H28FN5O4 (C26 H28 FN5 O4)

Compound Name

methyl 2-[(3-{[1-(4-fluorophenyl)-N-phenylformamido]methyl}-1-methyl-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-5-carbonyl)amino]propanoate

IUPAC name

methyl 2-[(3-{[1-(4-fluorophenyl)-N-phenylformamido]methyl}-1-methyl-1H4H5H6H7H-pyrazolo[43-c]pyridine-5-carbonyl)amino]propanoate

SMILES

CC(C(OC)=O)NC(N(CC1)Cc2c1n(C)nc2CN(C(c(cc1)ccc1F)=O)c1ccccc1)=O

InChI

InChI=1S/C26H28FN5O4/c1-17(25(34)36-3)28-26(35)31-14-13-23-21(15-31)22(29-30(23)2)16-32(20-7-5-4-6-8-20)24(33)18-9-11-19(27)12-10-18/h4-12,17H,13-16H2,1-3H3,(H,28,35)/t17-/m0/s1

InChI Key

TXHRQUSWIOVXAT-KRWDZBQOSA-N

MDL Number (MFCD)

MFCD27483055

Chemical and Physical Properties

Saltdata

n/a

Molecular Weight

493.54

Hydrogen Bond Acceptors Count

8.00

Hydrogen Bond Donors Count

1.00

Rotatable Bond Count

10.00

Number of Nitrogen and Oxygen Atoms

9

Partition Coefficient, logP

2.507

Distribution Coefficient, logD

2.507

Water Solubility, LogSw

-2.65

Polar Surface Area

78.164

Acid Dissociation Constant (pKa)

15.32

Base Dissociation Constant (pKb)

2.43

Number of Chiral Centers

1.00

Percent sp3 carbon bonding

30.80

L870-0113 in Drug Discovery

Included in Screening Libraries

Cysteine Proteases Inhibitors Library (7839 compounds)

Hsp90-Targeted Library (11355 compounds)

PPI Helix Turn 3D-Mimetics Library (71298 compounds)

Protein-Protein Interaction Library (218420 compounds)

Peptidomimetics of Beta-Turn Motifs Library (2153 compounds)

Included in 1.7M Stock Database

Therapeutical areas:
  • Infections
  • Cancer
  • Musculoskeletal
  • Digestive system
  • Nervous system
  • Cardiovascular
  • Skin
  • Metabolic
  • Endocrine
  • Immune system
  • Cancer
  • Digestive system
  • Respiratory tract
  • Male
  • Female
  • Hemic and lymphatic
  • Immune system
Targets:
  • Proteases
Mechanism of action:
  • PPI modulators
  • PPI modulators
  • PPI modulators
Structure:
  • Mimetics
  • Mimetics

References: we are preparing a list of scientific research reports with L870-0113 chemical compound. It will be published here after verification.

Frequently Asked Questions

How to purchase chemical compound L870-0113?
Check Price and Availability of L870-0113, then you can add required amount to the Shopping Cart. In the Shopping Cart you can again refine your selection. Once you are sure that it’s exactly what you want you can move forward with the Checkout (to pay online by credit card, or via PayPal), or Request a Quote.
What is the minimum amount of L870-0113 you sell to drug discovery company or institution?
Available from 1 mg in Glass Vials or 96-tube racks.
Delivery options for L870-0113
ChemDiv sends parcels with Express services (UPS, WC).
  • 1–2 days for small orders
  • 2–4 weeks for large selections
Delivery formats for L870-0113
  • 0.5–50 mg of dry powder sample in single glass vials, custom vials
  • DMSO solutions frozen 10μl–250μl@10mM (96 and 384 format)

Custom synthesis of L870-0113 available by request